EVOK Stock Analysis: Buy, Sell, or Hold?
EVOK - Evoke Pharma, Inc.
$10.99
0.03 (0.27%)
▲
5d:
+0.64%
30d:
+2.81%
90d:
+115.91%
BUY
MODERATE Confidence
Analysis Updated: Dec 16, 2025 12:00 AM ET
Get Alerted When EVOK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: EVOK shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: EVOK shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.29
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$8.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EVOK is currently trading at $10.99, which is considered fair based on recent price action. The stock's valuation (Forward PE: 16.2) is in line with its historical norms (15.0). At these levels, the market is pricing in 2.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVOK is in a strong uptrend. The price is currently testing key support at $10.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.00 (+63.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, EVOK is in a strong uptrend. The price is currently testing key support at $10.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.00 (+63.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
56/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
68.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Trading 63.8% below Wall St target ($18.00)
- NEUTRAL: Market pricing in 2.6% annual earnings growth - fairly valued
Support & Resistance Levels
Support Level
$10.90
Resistance Level
$11.00
Current Trend
Strong Uptrend
Technical data as of
Dec 16, 2025
Fundamental Context
Forward P/E (Next Year Est.)
16.16
Wall Street Target
$18.00
(+63.8%)
Revenue Growth (YoY)
61.4%
Profit Margin
-36.2%
Valuation Premium vs History
+2.6% premium
PE vs Historical
16.2 vs 15.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$11.28
(+3%)
2-Year Target
$11.57
(+5%)
3-Year Target
$11.87
(+8%)
3-Yr Target (if PE normalizes)
(PE: 16→15)
PE COMPRESSION
$11.02
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: May 09, 2026 2:04 AM ET
Data refreshes hourly during market hours. Next update: 3:04 AM
Data refreshes hourly during market hours. Next update: 3:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVOK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 66 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$96 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$149 | 52 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |
